Integrated Filing — IndAS



General information about company

Scrip Code 543245
NSE Symbol GLAND
MSEI Symbol NOTLISTED
ISIN INE068V01023
Name of company GLAND PHARMA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 06-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 21-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 06-11-2026   15:00:00
End date and time of board meeting 06-11-2026   16:15:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 20-05-2025
Indicate Company website link for updated RPT policy of the Company https://glandpharma.com/images/Policy_of_Related_Party_Transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not applicable for the quarter



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 1,40,190.20 2,68,854.20
Other income 7,138.30 13,020.40
Total income 1,47,328.50 2,81,874.60
2 Expenses
(a) Cost of materials consumed 52,041.90 98,986.50
(b) Purchases of stock-in-trade 313.60 508.10
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 23.20 3,608.80
(d) Employee benefit expense 14,959.90 29,350.80
(e) Finance costs 315.00 384.10
(f) Depreciation, depletion and amortisation expense 4,514.80 8,910.10
(f) Other Expenses
1 Power and fuel 3,996.10 7,359.30
2 Other expenses 14,086.90 26,920.80
Total other expenses 18,083.00 34,280.10
Total expenses 90,251.40 1,76,028.50
3 Total profit before exceptional items and tax 57,077.10 1,05,846.10
4 Exceptional items 0.00 0.00
5 Total profit before tax 57,077.10 1,05,846.10
6 Tax expense
7 Current tax 14,676.80 27,196.00
8 Deferred tax (87.30) (276.60)
9 Total tax expenses 14,589.50 26,919.40
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 42,487.60 78,926.70
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 42,487.60 78,926.70
17 Other comprehensive income net of taxes (326.30) (164.40)
18 Total Comprehensive Income for the period 42,161.30 78,762.30
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,650.10 1,650.10
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 25.75 47.86
Diluted earnings (loss) per share from continuing operations 25.75 47.86
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 25.75 47.86
Diluted earnings (loss) per share from continuing and discontinued operations 25.75 47.86
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Refer the signed results uploaded for the complete notes.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1,64,461.70
Capital work-in-progress 19,092.30
Investment property 0.00
Goodwill 0.00
Other intangible assets 165.80
Intangible assets under development 263.20
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 3,29,255.20
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
Total of other non-current financial assets
Total non-current financial assets 3,29,255.20
Deferred tax assets (net) 0.00
Other non-current assets
1 Tax assets, net 533.70
2 Other non-current assets 11,603.30
3 Right-of-use assets 240.70
Total of other non-current assets 12,377.70
Total non-current assets 5,25,615.90
2 Current assets
Inventories 1,36,171.80
Current financial asset
Current investments 0.00
Trade receivables, current 1,64,517.80
Cash and cash equivalents 3,37,298.70
Bank balance other than cash and cash equivalents 0.00
Loans, current 0.00
Other current financial assets
Total of other current financial assets 12,171.10
Total current financial assets 5,13,987.60
Current tax assets (net) 0.00
Other current assets
1 Other current assets 46,998.60
Total of other current assets 46,998.60
Total current assets 6,97,158.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 12,22,773.90
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,650.10
Other equity 11,30,411.40
Total equity attributable to owners of parent 11,32,061.50
Non controlling interest
Total equity 11,32,061.50
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease liabilities 254.60
Total of other non-current financial liabilities 254.60
Total non-current financial liabilities 254.60
Provisions, non-current 5,572.30
Deferred tax liabilities (net) 11,143.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 16,969.90
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 1,900.90
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 56,153.10
Total Trade payable 58,054.00
Other current financial liabilities
1 Other financial liabilities 2,061.40
2 Lease liabilities 23.30
Total of other current financial liabilities 2,084.70
Total current financial liabilities 60,138.70
Other current liabilities 7,204.00
1 Other current liabilities 7,204.00
Total of other current liabilities 7,204.00
Provisions, current 983.30
Current tax liabilities (Net) 5,416.50
Deferred government grants, Current 0.00
Total current liabilities 73,742.50
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 90,712.40
Total equity and liabilites 12,22,773.90
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit plans (436.00) (219.70)
Total Amount of items that will not be reclassified to profit and loss (436.00) (219.70)
2 Income tax relating to items that will not be reclassified to profit or loss (109.70) (55.30)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (326.30) (164.40)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1,05,846.10
Adjustments for reconcile profit (loss)
Adjustments for finance costs 384.10
Adjustments for decrease (increase) in inventories (9,652.10)
Adjustments for decrease (increase) in trade receivables, current (11,880.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (8,933.30)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 8,582.60
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 8,910.10
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 2,868.40
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (2,896.00)
Adjustments for dividend income 0.00
Adjustments for interest income 11,108.10
Adjustments for share-based payments 3,983.60
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (195.40)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (19,936.10)
Net cash flows from (used in) operations 85,910.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 27,302.20
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 58,607.80
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 16,333.20
Proceeds from sales of investment property 77.30
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 263.20
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 6,477.30
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 267.80
Net cash flows from (used in) investing activities (9,774.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 1,305.60
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 0.00
Dividends paid 32,987.40
Interest paid 224.80
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (31,906.60)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 16,927.20
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 2,607.60
Net increase (decrease) in cash and cash equivalents 19,534.80
Cash and cash equivalents cash flow statement at beginning of period 3,17,763.90
Cash and cash equivalents cash flow statement at end of period 3,37,298.70





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Deloitte Haskins & Sells Yes 30-04-2028


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Gland Pharma Limited Chongqing Carelife Pharmaceutical Co., Ltd Fellow subsidiary Purchase of goods or services 1,056.70 NA 857.40 0.00 0.00
2 Gland Pharma Limited Fosun Pharma USA Inc. Fellow subsidiary Any other transaction Reimbursement of Expenses 2,000.00 NA 1,609.50 0.00 0.00
3 Gland Pharma Limited Fosun Pharma USA Inc. Fellow subsidiary Sale of goods or services 25,000.00 NA 23,858.60 6,786.40 18,659.20
4 Gland Pharma Limited Gland Pharma International Pte Ltd. Wholly Owned Subsidiary Sale of goods or services 25,000.00 NA 4,191.70 1,212.40 1,986.60
5 Gland Pharma Limited Fosun Wanbang (Jiangsu) Pharmaceutical Group CO., LTD. Formerly known as Wangbang Biopharmaceuticals) Fellow subsidiary Sale of goods or services 1,000.00 NA 111.60 0.00 0.00
6 Gland Pharma Limited Phixen SAS and its subsidiaries Wholly owned step down subsidiaries Purchase of goods or services 6,600.00 NA 2,729.80 0.00 0.00
7 Gland Pharma Limited Phixen SAS and its subsidiaries Wholly owned step down subsidiaries Any other transaction Reimbursement of Expenses 1,100.00 NA 2.20 0.00 0.00
8 Gland Pharma International Pte Ltd. Phixen SAS and its subsidiaries Wholly owned step down subsidiaries Loan 55,000.00 NA 6,598.80 0.00 0.00
9 Gland Pharma Limited Shanghai Fosun Pharmaceutical Industrial Development Co Ltd Fellow subsidiary Purchase of goods or services 200.00 NA 59.50 (26.50) (86.30)
10 Gland Pharma Limited Hunan Dongting Pharmaceutical Co.,Ltd. Fellow subsidiary Purchase of goods or services 460.00 NA 130.10 0.00 0.00
11 Gland Pharma Limited Fosun Pharma SAS Fellow subsidiary Sale of goods or services 3,050.00 NA 182.60 603.80 0.00
12 Gland Pharma Limited Fosun Pharma SAS Fellow subsidiary Any other transaction Reimbursement of Expenses 100.00 NA 13.20 0.00 0.00
13 Gland Pharma Limited Shanghai Ddsome Laboratories Co., Ltd Fellow subsidiary Purchase of goods or services 1,900.00 NA 263.20 0.00 478.50
14 Gland Pharma Limited Srinivas Sadu Director Remuneration 1,451.60 NA 1,451.60 (287.40) (112.50)
15 Gland Pharma International Pte Ltd. Srinivas Sadu Director Remuneration 148.80 NA 148.80 0.00 (12.00)
16 Gland Pharma Limited Ravi Shekhar Mitra Key Managerial Personnel Remuneration 584.60 NA 584.60 (98.80) (57.60)
17 Gland Pharma Limited Satyanarayana Murthy Chavali Director Any other transaction Sitting Fees 9.00 NA 9.00 0.00 0.00
18 Gland Pharma Limited William Robert Keller Director Any other transaction Sitting Fees 5.00 NA 5.00 0.00 0.00
19 Gland Pharma Limited William Robert Keller Director Any other transaction Commission 27.50 NA 27.50 0.00 (27.50)
20 Gland Pharma Limited Udo J. Vetter Director Any other transaction Sitting Fees 13.00 NA 13.00 0.00 0.00
21 Gland Pharma Limited Udo J. Vetter Director Any other transaction Commission 27.50 NA 27.50 (17.20) (27.50)
22 Phixen SAS Udo J. Vetter Director Remuneration 20.40 NA 20.40 0.00 (20.40)
23 Gland Pharma Limited Essaji Goolam Vahanvati Director Any other transaction Sitting Fees 13.00 NA 13.00 0.00 0.00
24 Gland Pharma Limited Essaji Goolam Vahanvati Director Any other transaction Commission 27.50 NA 27.50 (22.50) (27.50)
25 Gland Pharma Limited Nainalal Kidwai Director Any other transaction Sitting Fees 6.00 NA 6.00 0.00 0.00
26 Gland Pharma Limited Nainalal Kidwai Director Any other transaction Commission 50.00 NA 50.00 (90.00) (50.00)
27 Gland Pharma Limited P. Sampath Kumar Key Managerial Personnel Remuneration 149.50 NA 149.50 (3.40) (10.20)
28 Gland Pharma Limited Fosun Wanbang (Jiangsu) Pharmaceutical Group CO., LTD. Formerly known as Wangbang Biopharmaceuticals) Fellow subsidiary Purchase of goods or services 17,537.10 NA 0.00 (94.90) 0.00
29 Gland Pharma Limited Shanghai Henlius Biotech Inc. Fellow subsidiary Any other transaction Reimbursement of Expenses NA 0.00 108.90 0.00
30 Gland Pharma Limited Satyanarayana Murthy Chavali Director Any other transaction Commission NA 0.00 (22.50) 0.00
31 Gland Pharma International Pte Ltd. Satyanarayana Murthy Chavali Director Remuneration NA 0.00 (19.00) 0.00
Total value of transaction during the reporting period 43,141.60